Horizon Europe's 2027 Health Calls: €528 Million, a February 17 Deadline, and an Open Door for US Institutions
November 15, 2026 · 7 min read
Granted Research Team · Editorial policy
In most of Horizon Europe, a US university can join a consortium but has to pay its own way. The European Union's flagship research program generally doesn't fund institutions in high-income countries that aren't formally associated with it, and the United States isn't associated.
The Health cluster is the exception. Every topic in the 2027 Health calls carries the same clause in the official work programme: "In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding."
That clause matters more this cycle than usual. The European Health and Digital Executive Agency (HaDEA) opened the 2027 Health calls on October 29, 2026: 14 topics, all due February 17, 2027, at 17:00 Brussels time. By the budget tables in the Cluster 1 Health work programme for 2026-2027, the two calls with that deadline total €528.2 million. A third call worth €81.5 million opens in June 2027.
For American investigators facing a constrained NIH payline and policy uncertainty, here is how to read the opportunity.
Two Calls, One Date, Very Different Mechanics
The February 17 deadline covers two calls that work differently.
HORIZON-HLTH-2027-01 (single stage, €341.6 million). Ten topics. Applicants submit a full proposal by February 17, and that's the only submission:
| Topic | Type | Budget | Per project | Projects |
|---|---|---|---|---|
| STAYHLTH-01: Disabilities through the life course | RIA | €39.3M | €6–8M | 5 |
| ENVHLTH-02: Climate exposures in the human exposome | RIA | €45.0M | €10–11M | 4 |
| ENVHLTH-MISSCLIMA-03: Health adaptation to climate change | PCP | €20.0M | €4–5M | 4 |
| DISEASE-05: Small-molecule antivirals, epidemic pathogens | RIA | €44.2M | €9–11M | 5 |
| DISEASE-06: Monoclonal antibodies, flaviviruses | RIA | €37.3M | €9–10M | 4 |
| DISEASE-07: Monoclonal antibodies, filo-/nairo-/phenui-/picorna-/togaviruses | RIA | €37.3M | €9–10M | 4 |
| DISEASE-08: Antimicrobials against resistant pathogens | RIA | €44.2M | €8–10M | 5 |
| DISEASE-10: Pediatric chronic NCDs (GACD) | RIA | €11.8M | €3–4M | 3 |
| CARE-02: Adverse drug reactions from polypharmacy | RIA | €38.0M | €8–10M | 4 |
| IND-01: Cell-free protein synthesis platforms | RIA | €24.5M | €6–8M | 4 |
HORIZON-HLTH-2027-02-two-stage (€186.6 million). Four topics. February 17 is the first-stage deadline, and invited consortia submit full proposals by September 16, 2027:
| Topic | Type | Budget | Per project | Projects |
|---|---|---|---|---|
| DISEASE-01: Healthcare interventions for NCDs | RIA | €63.8M | €7–8M | 8 |
| DISEASE-14: Clinical trials, neurodegenerative disease | RIA | €39.3M | ~€10M | 4 |
| TOOL-01: AI-derived predictive biomarkers for chronic NCDs | RIA | €44.2M | €6–8M | 6 |
| IND-02: Portable point-of-care diagnostics | IA | €39.3M | €5–7M | 6 |
A third call, HORIZON-HLTH-2027-03, opens June 3, 2027 and closes September 16, 2027. It covers bio-printing for regenerative medicine (€39.3M), virtual human twins for clinical decision support (€39.3M), and a €2.9M coordination action on frontier AI models for healthcare. Teams that can't meet February 17 should look there.
Per-project sizes are large by NIH standards. An antimicrobial consortium budgeted at €8–10 million over four or five years is several R01s' worth of funding. It is also split across many partners, typically six to fifteen institutions in multiple countries, so a single US lab's share is usually a few hundred thousand to a couple of million euros.
Why the US Exception Exists, and What It Doesn't Cover
The US funding clause is reciprocal. It reflects NIH's openness to foreign applicants and has appeared in Health cluster work programmes for years. It appears in every 2027 topic we checked, including the two-stage topics and the climate PCP.
It doesn't change the consortium rules. Standard Horizon Europe research and innovation actions still require at least three independent legal entities from three different EU member states or associated countries, with at least one from a member state. A US institution is an extra partner, not a substitute for the European core. In practice, a US team joins a European-led consortium. It doesn't build one around itself.
The clause also doesn't remove the other conditions that apply to everyone. Several topics include the restriction "for the protection of European communication networks," and any project using satellite earth-observation data must use Copernicus or Galileo/EGNOS. US institutions should also expect the standard Horizon Europe grant agreement. On the topics we reviewed, that agreement lets the granting authority object, for up to four years after the project ends, to a transfer of ownership or exclusive licensing of results. Technology transfer offices should read that provision before a PI commits.
On the US side, a Horizon Europe subaward is foreign funding that must be disclosed in NIH and NSF other-support and current-and-pending documents. It's allowed and common, but it has to be reported.
The Two-Stage Topics Are Built to Be Oversubscribed
The four two-stage topics publish their own filtering rules, and those rules give a rough sense of the odds.
For DISEASE-01 (NCD healthcare interventions), the first-stage threshold is set so that "the total requested budget of proposals admitted to stage 2 is as close as possible to three times the available budget." For TOOL-01 (AI biomarkers), the multiplier is four times. Put differently, roughly one in three DISEASE-01 second-stage proposals and one in four TOOL-01 second-stage proposals will be funded. Getting through the first stage is only the first cut.
The first stage of each two-stage topic is also evaluated blindly. Applicants "must not disclose their organisation names, acronyms, logos nor names of personnel in the proposal abstract and Part B of their first-stage application." Teams used to NIH's biosketch-driven review, where investigator track record is a scored criterion, need to write differently. The science and the impact pathway have to carry the proposal without the names attached. A well-known consortium can't rely on its reputation, and the rule is meant to give lesser-known groups a fairer read.
The AI biomarkers topic is likely to draw the most US interest. It asks for "novel predictive biomarkers to guide a more accurate assessment of disease progression and treatment response" in chronic non-communicable diseases using AI methods. That matches much of the computational medicine work NIH has funded. It is also the most competitive topic in the call by design.
Higher Bars on the Single-Stage Disease Topics
Several single-stage topics, including the antiviral (DISEASE-05) and pediatric NCD (DISEASE-10) topics, raise the evaluation thresholds. Each criterion must score at least 4 out of 5 (excellence, impact, implementation), with a cumulative minimum of 12. Horizon Europe's general default is 3 per criterion and 10 overall. A proposal that is excellent scientifically but vague on exploitation or management won't make the funding line.
Other topic-level details to note:
- DISEASE-05 (antivirals) awards grants "not only in order of ranking." To keep a balanced portfolio across the virus families listed in the scope, the agency will also fund the top-ranked proposal for each virus or virus group, as long as it clears all thresholds. Targeting a less-crowded family can be a deliberate strategy.
- DISEASE-10 (pediatric chronic disease) is part of the Global Alliance for Chronic Diseases (GACD), where NIH institutes have historically been co-members. It is funded as a lump sum, so reviewers judge the work-package budget up front and there is no line-item cost reporting afterward. It focuses on low- and middle-income countries and disadvantaged populations in high-income countries. US implementation-science groups with LMIC partners fit well.
- ENVHLTH-MISSCLIMA-03 is a pre-commercial procurement (PCP) action. Public health buyers jointly procure R&D of climate-adaptation tools, rather than the usual researcher-led grant. €10 million of its €20 million budget comes from the Climate, Energy and Mobility cluster. US vendors can compete in PCP tenders, but the consortium of buyers is European.
All deadlines are subject to the work programme's usual caveat: the responsible Director-General "may delay the deadline(s) by up to two months," and budgets depend on the EU's 2027 appropriations. Plan for February 17.
A 94-Day Plan for US Teams
Joining a Horizon Europe consortium from outside the EU has a fixed order of steps.
Before November 26. Register for the online brokerage event on November 24–25 and the HaDEA Health info day on Thursday, November 26, which runs online starting at 09:00 CET (3:00 a.m. Eastern). The brokerage event is where European coordinators look for the expertise they're missing. A US group with a unique cohort, assay platform, or clinical trial network should show up with a one-page capability statement.
By mid-December. Get your institution a Participant Identification Code (PIC) on the EU Funding & Tenders Portal, and agree on your role with a coordinator. Coordinators lock consortia six to eight weeks before deadline. A US partner approaching a consortium in late January will usually find the budget already allocated.
January. Draft your work-package contributions to the coordinator's template. Confirm with your sponsored programs office that it can handle an EU grant agreement, which is signed by the coordinator with partners acceding, and a consortium agreement, which is negotiated separately and often based on the DESCA model.
For two-stage topics. Remember that the February first-stage submission is short and anonymous. The full budget and partner details come in September, which gives US partners more time to sort out institutional approvals.
When US research budgets are uncertain, a European health consortium can be a way to diversify funding without changing your science. The 2027 calls are large and open to US institutions on every topic. The real constraint is time: consortia are being formed now. Granted can help you turn a capability statement into the work-package narrative a European coordinator needs from you before the February 17 deadline.